Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vichin Puri

Transplant Surgery Dallas, TX Medical Doctor

NPI 1003060211 CMS profile 1290176

1411 N. Beckley Ave., Pavilion Iii, Suite 268, Dallas, TX 75203

Open in the dashboard

General payments

$2,132

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vichin Puri of Dallas, TX is reported in the CMS Open Payments database as having received $2,132 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Transplant Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $553 8
2024 General $161 8
2023 General $332 14
2022 General $159 8
2021 General $680 25
2020 General $159 10
2019 General $89 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vichin Puri
  • Transplant Surgery median
  • Middle half of Transplant Surgery
  • National median

In program year 2025, general payments to Vichin Puri were reported at $553. Among 555 Transplant Surgery profiles paid that year, the median was $421 and the middle half received between $116 and $2,169.

Show as a table
Year Vichin Puri Transplant Surgery median Middle half National median
2019 $89 $203 $77–$1,249 $163
2020 $159 $149 $52–$1,366 $114
2021 $680 $168 $73–$2,008 $132
2022 $159 $213 $94–$1,464 $149
2023 $332 $262 $93–$1,458 $160
2024 $161 $354 $126–$2,252 $164
2025 $553 $421 $116–$2,169 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $381 24 payments
  2. Intercept Pharmaceuticals, Inc. $285 15 payments
  3. Histosonics, Inc. $279 2 payments
  4. AbbVie, Inc. $240 11 payments
  5. Gilead Sciences, Inc. $187 10 payments
  6. Stryker Corporation $171 1 payment
  7. C. R. Bard, Inc. & Subsidiaries $153 1 payment
  8. Eurofins Viracor, Inc. $129 1 payment
  9. HemoSonics LLC $66 1 payment
  10. Eisai Inc. $46 2 payments
  11. Other $195 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,132 78 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $381 24 payments
  2. OCALIVA $260 13 payments
  3. SPY-PHI SYSTEM $171 1 payment
  4. Phasix Mesh $153 1 payment
  5. MAVYRET $136 7 payments
  6. AVYCAZ $76 3 payments
  7. QUANTRA QPLUS SYSTEM $66 1 payment
  8. QUANTRA QPLUS SYSTEM Hematology $66 1 payment
  9. Lenvima $46 2 payments
  10. CREON $28 1 payment
  11. Other $270 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$59,722

Medicare's payments for the services billed

Medicare patients

91

Average age 64

Services billed

227

38 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 67%
Diabetes 60%
Arthritis 46%
Heart failure 34%
Ischemic heart disease 33%
Atrial fibrillation 30%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OCALIVA
  • INTERCEPT PHARMACEUTICALS, INC. $99
$99 — —
CREON
  • AbbVie, Inc. $28
$28 — —
Lenvima
  • Eisai Inc. $17
$17 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Transplant Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record